Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button

Home > Press > CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug

Abstract:
Leuchemix Corporation announced that permission to undertake clinical safety trials of its drug LC-1, for leukemia, has been granted and that the sponsored trial will begin shortly.

CombiMatrix Announces That Permission Has Been Granted to Begin Clinical Trial for Leuchemix Drug

MUKILTEO, WA | Posted on September 29th, 2008

CombiMatrix Corporation (Nasdaq:CBMX) owns one third of Leuchemix.

####

About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce customizable, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), a wholly owned subsidiary of the Company located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or call toll free: 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory, and competitive developments, and general economic conditions. Our Annual Report, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
CombiMatrix Corporation
Investor Relations
Amit Kumar, President and CEO
(425) 493-2000
Fax: (425) 493-2010

Copyright © GlobeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

Novel state of matter: Observation of a quantum spin liquid July 29th, 2016

A new type of quantum bits July 29th, 2016

Nanomedicine

Scientists change properties of zeolites to improve hemodialysis July 29th, 2016

Pixel-array quantum cascade detector paves the way for portable thermal imaging devices: Research team from TU-Wien Center for Micro- and Nanostructures have developed a new 'cooler' sensing instrument thereby increasing energy-efficiency and enhancing mobility for diagnostic tes July 28th, 2016

Starpharma initiates new DEPô drug delivery program with AstraZeneca July 27th, 2016

Scientists test nanoparticle drug delivery in dogs with osteosarcoma July 26th, 2016

Announcements

Vortex laser offers hope for Moore's Law: The optics advancement may solve an approaching data bottleneck by helping to boost computing power and information transfer rates tenfold July 30th, 2016

New method for making green LEDs enhances their efficiency and brightness July 30th, 2016

Novel state of matter: Observation of a quantum spin liquid July 29th, 2016

A new type of quantum bits July 29th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic